Dyrupeg, used to reduce the risk of infection in patients undergoing chemotherapy, had earlier secured marketing authorisation from the European Commission in April 2025. Shares of Aurobindo Pharma Ltd ended at ₹1,106.40, up by ₹6.65, or 0.60%, on the BSE.
